- Home
- CAST vs TCRX Comparison
CAST vs TCRX Comparison
Compare CAST & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAST | TCRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 49.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAST | TCRX |
|---|---|---|
| Price | $1.02 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 318.7K | ★ 623.0K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | $710,882.00 | ★ $10,325,000.00 |
| Revenue This Year | $323.40 | N/A |
| Revenue Next Year | $1,478.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.17 | ★ 266.65 |
| 52 Week Low | $0.50 | $0.20 |
| 52 Week High | $12.20 | $2.43 |
Technical Indicators
Market Signals| Indicator | CAST | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 29.88 |
| Support Level | $0.83 | $0.20 |
| Resistance Level | $1.53 | $0.37 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 22.00 | 14.93 |
Price Performance
Historical ComparisonAbout CAST FreeCast Inc. Class A Common Stock
FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and other streaming services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.